Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

NCT01186991 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Onartuzumab
DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: Bevacizumab Placebo
DRUG: Onartuzumab Placebo

Sponsor

Genentech, Inc.

Collaborators

[object Object]